Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
ACVRL1 encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands.
Showing 10 out of 173 products:
Human Polyclonal ACVRL1 Primary Antibody for FACS, IHC (p) - ABIN392241
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 5 Pubmed References
Human Polyclonal ACVRL1 Primary Antibody for ELISA, WB - ABIN250173
Johnson, Berg, Baldwin, Gallione, Marondel, Yoon, Stenzel, Speer, Pericak-Vance, Diamond, Guttmacher, Jackson, Attisano, Kucherlapati, Porteous, Marchuk: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. in Nature genetics 1996
Human Polyclonal ACVRL1 Primary Antibody for IHC, IHC (p) - ABIN4279393
Cunha, Pardali, Thorikay, Anderberg, Hawinkels, Goumans, Seehra, Heldin, ten Dijke, Pietras: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. in The Journal of experimental medicine 2010
Human Polyclonal ACVRL1 Primary Antibody for WB - ABIN1944774
Berg, Gallione, Stenzel, Johnson, Allen, Schwartz, Jackson, Porteous, Marchuk: The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. in American journal of human genetics 1997
Show all 3 Pubmed References
Results show that ALK5 (show TGFBR1 Antibodies) and ALK1 play antagonistic roles in TGF-beta (show TGFB1 Antibodies)-induced podosome formation in aortic endothelial cells.
ALK1 and ALK5 (show TGFBR1 Antibodies) are both essential for correct regulation of VEGF (show VEGFA Antibodies), and that disruption of either pathway leads to disease.
alk1 loss has no effect on arterial endothelial cell proliferation but alters arterial endothelial cell migration within lumenized vessels.
Control of Notch (show NOTCH1 Antibodies) targets in arterial endothelium is context-dependent, with gene-specific and region-specific requirements for Notch (show NOTCH1 Antibodies) and Alk1
Blood flow is required not only for alk1 expression but also for Alk1 activity.
Study demonstrate that alk1 expression requires blood flow, and despite normal levels of shear stress, some flow-responsive genes are dysregulated in alk1 mutant arterial endothelial cells.
vbg encodes activin receptor-like kinase 1 (acvrl1), a TGFbeta (show TGFB1 Antibodies) type I receptor that is expressed predominantly in the endothelium of the vessels that become dilated in vbg mutants.
The present study showed that deletion-duplication mutations in the BMPR2 (show BMPR2 Antibodies) or ACVRL1 genes may not be associated with non-regression of Pulmonary arterial hypertension.
Study identified 2 non-synonymous missense mutations: c.C652T, p.R218W in ACVRL1, c.C717G, p.D239E in SGCD (show SGCD Antibodies) in Chinese population with total anomalous pulmonary venous return.
Mutations in ACVRL1 gene encoding for transforming growth factor (TGF)-[beta] superfamily have been identified in Pulmonary Arterial Hypertension.
Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway.
Data indicate that simultaneous targeting of molecules that control distinct phases of angiogenesis, such as ALK1 and VEGFR (show KDR Antibodies), is a valid strategy for treatment of metastatic renal cell carcinoma (show MOK Antibodies) (mRCC).
Study showed that rs706819, rs2293094, and rs11169953 polymorphisms in the ACVRL1 gene are associated with higher susceptibility to brain arteriovenous malformations.
c.1027C > T(p.Gln343) mutation within the ACVRL1 gene in family with hereditary hemorrhagic telangiectasia
Bone morphogenetic protein (BMP)9 (show GDF2 Antibodies) and BMP10 (show BMP10 Antibodies) are high affinity ligands for activin receptor-like kinase 1 (ALK1).
Activin receptor-like kinase (ALK)1 is a transforming growth factor beta (TGF-beta) type I receptor (show TGFBR1 Antibodies) predominantly expressed in actively proliferating endothelial cells (ECs).
Two novel missense mutations and two recurrent mutations in the ACVRL1 gene are associated with pulmonary arterial hypertension in in Chinese families.
Data show that concomitant activin receptor-like kinase 1 (Acvrl1) and endoglin (Eng (show ENG Antibodies)) deficiency synergistically decreases pancreatic neuroendocrine tumor volume.
Global deletion of AlK-1 is associated with the development of high output heart failure without maladaptive remodeling.
These data indicate that both Itgb8 and Alk1 are important in maintaining normal cerebral angiogenesis in response to VEGF (show VEGFA Antibodies). Itgb8 deficiency enhances the formation of dysplastic vessels and hemorrhage in Alk1 (+/-) mice.
these studies characterize an accessory TGF-beta (show TGFB1 Antibodies)-stimulated BMP R-Smad (show SMAD1 Antibodies) signaling mechanism in interstitial cells of the developing lung.
this study demonstrates that ACVRL1 signaling plays a pivotal role whereby it suppresses plasmacytoid dendritic cell development while enhancing that of CD8alpha(+) dendritic cells, thus contributing to DC diversity development.
CD109 (show CD109 Antibodies) differentially regulates TGF-beta (show TGFB1 Antibodies)-induced ALK1-Smad1 (show SMAD1 Antibodies)/5 versus ALK5 (show TGFBR1 Antibodies)-Smad2 (show SMAD2 Antibodies)/3 pathways, leading to decreased extracellular matrix production in the skin; epidermal CD109 (show CD109 Antibodies) expression regulates dermal function through a paracrine mechanism
he results of the present study demonstrated that BMP9 promoted the osteoclast differentiation of osteoclast precursors via binding to the ALK1 receptor on the cell surface, and inhibiting the ERK1/2 signaling pathways in the cell
Conclude that the ALK-1 receptor is involved in the control of arterial pressure. High AP of Alk1(+/-) mice is explained mainly by the sympathetic overactivation, which is probably related to the decreased number of cholinergic neurons.
Report interaction between ALK1 signaling and connexin40 in the development of arteriovenous malformations.
In vascular sprouting, neuropilin-1 (show NRP1 Antibodies) suppresses the stalk-cell phenotype by limiting Smad2 (show SMAD2 Antibodies)/3 activation through Alk1 and Alk5 (show TGFBR1 Antibodies). Notch (show NOTCH1 Antibodies) downregulates Nrp1 (show NRP1 Antibodies), thus relieving the inhibition of Alk1 and Alk5 (show TGFBR1 Antibodies), thereby driving stalk-cell behaviour.
This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2.
activin A receptor type II-like 1
, serine/threonine-protein kinase receptor R3
, serine/threonine-protein kinase receptor R3-like
, activin receptor-like kinase 1
, violet beauregarde
, TGF-B superfamily receptor type I
, activin A receptor, type II-like kinase 1
, Activin receptor like kinase 1
, activin receptor-like kinase-1